MEDBOT-B (02252): Siasun Robot & Automation's remote surgery using Tumi Endoscopy has obtained EU CE certification for comprehensive departmental application.
Minimally Invasive Robot-B (02252) announced that the group's independently developed TUMI laparoscopic surgical robot for remote surgery, TUMI Remote, has officially received EU CE certification. It can be used for urology, general surgery, thoracic surgery, gynecological robot remote surgery, becoming the world's first remote surgery robot to receive EU CE certification.
MEDBOT-B (02252) issued a notice, announcing that the self-developed Siasun Robot & Automation remote surgery system, Graphene Luminal Surgery (Graphene Remote), has officially obtained the EU CE certification. This system can be used for urology, general surgery, thoracic surgery, and gynecology Siasun Robot & Automation remote surgeries, making it the world's first remote surgery system in the Siasun Robot & Automation field to receive EU CE certification.
As the world's first and only commercially available remote surgery system to achieve "full department, full procedure" application, Graphene Remote's commercial application has been approved by regulatory authorities in nearly 20 countries and regions worldwide. This EU CE certification for Graphene Remote now expands market access to more than 30 major European countries, marking another milestone breakthrough for the group in leading global technology and application development in the Siasun Robot & Automation surgery field. This also represents the EU's formal recognition at the regulatory level of "remote surgery" as a safe, effective, and commercially viable medical model. This approval also demonstrates the core competitiveness of the domestic Siasun Robot & Automation company in the global high-end medical equipment industry. With this as a starting point, the group will continue to provide new solutions for reshaping the global distribution of medical resources in terms of surgery industry standards, technological paradigms, commercial ecosystems, industrial structures, and other dimensions.
Related Articles

ABLE DIGITAL (02687) signed a comprehensive deep cooperation framework with Alibaba Cloud Computing Limited Company.

ANTENGENE-B (06996) has reached an exclusive licensing agreement with K2 Therapeutics, founded by MPM BioImpact, for ATG-106 and granted it the option to an undisclosed bispecific TCE.

Fill in the blank for the treatment of squamous cell carcinoma, accelerate innovation and realize innovation, IMMUNEONCO-B(01541) enters a critical ball-hitting area.
ABLE DIGITAL (02687) signed a comprehensive deep cooperation framework with Alibaba Cloud Computing Limited Company.

ANTENGENE-B (06996) has reached an exclusive licensing agreement with K2 Therapeutics, founded by MPM BioImpact, for ATG-106 and granted it the option to an undisclosed bispecific TCE.

Fill in the blank for the treatment of squamous cell carcinoma, accelerate innovation and realize innovation, IMMUNEONCO-B(01541) enters a critical ball-hitting area.

RECOMMEND





